Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models

Autor: Bridgeman, VL, Vermeulen, PB, Foo, S, Bilecz, A, Daley, F, Kostaras, E, Nathan, MR, Wan, E, Frentzas, S, Schweiger, T, Hegedus, B, Hoetzenecker, K, Renyi-Vamos, F, Kuczynski, EA, Vasudev, NS, Larkin, J, Gore, M, Dvorak, HF, Paku, S, Kerbel, RS, Dome, B, Reynolds, AR

Publikováno v: The Journal of Pathology

Anti‐angiogenic therapies have shown limited efficacy in the clinical management of metastatic disease, including lung metastases. Moreover, the mechanisms via which tumours resist anti‐angiogenic therapies are poorly understood. Importantly, rat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::8c406c28e5de15afb9f0c82b91706c95
https://pubmed.ncbi.nlm.nih.gov/27859259

A preclinical model of peripheral T-cell lymphoma GATA3 reveals DNA damage response pathway vulnerability.

Autor: Kuczynski EA; Oncology R&D, AstraZeneca, Cambridge, UK., Morlino G; Immunity & Cancer Laboratory, Francis Crick Institute, London, UK., Peter A; Oncology R&D, AstraZeneca, Cambridge, UK., Coenen-Stass AML; Oncology R&D, AstraZeneca, Cambridge, UK., Moss JI; Oncology R&D, AstraZeneca, Cambridge, UK., Wali N; Oncology R&D, AstraZeneca, Cambridge, UK., Delpuech O; Oncology R&D, AstraZeneca, Cambridge, UK., Reddy A; Oncology R&D, AstraZeneca, Waltham, MA, USA., Solanki A; Oncology R&D, AstraZeneca, Cambridge, UK., Sinclair C; Oncology R&D, AstraZeneca, Cambridge, UK., Calado DP; Immunity & Cancer Laboratory, Francis Crick Institute, London, UK.; Peter Gorer Department of Immunobiology, School of Immunology & Microbial Sciences, London, UK., Carnevalli LS; Oncology R&D, AstraZeneca, Cambridge, UK.

Publikováno v: EMBO molecular medicine [EMBO Mol Med] 2022 Jun 08; Vol. 14 (6), pp. e15816. Date of Electronic Publication: 2022 May 05.

Vessel co-option in cancer.

Autor: Kuczynski EA; Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, UK. elizabeth.kuczynski@astrazeneca.com.; Biological Sciences Platform, Sunnybrook Research Institute, Toronto, Canada. elizabeth.kuczynski@astrazeneca.com., Vermeulen PB; HistoGeneX, Antwerp, Belgium.; Translational Cancer Research Unit, GZA Hospitals St Augustinus, University of Antwerp, Wilrijk-Antwerp, Belgium.; Tumour Biology Team, Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK., Pezzella F; Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK., Kerbel RS; Biological Sciences Platform, Sunnybrook Research Institute, Toronto, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, Canada., Reynolds AR; Tumour Biology Team, Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK. andrew.reynolds1@astrazeneca.com.; Oncology Translational Medicine Unit, IMED Biotech Unit, AstraZeneca, Cambridge, UK. andrew.reynolds1@astrazeneca.com.

Publikováno v: Nature reviews. Clinical oncology [Nat Rev Clin Oncol] 2019 Aug; Vol. 16 (8), pp. 469-493.

Non-angiogenic tumours and their influence on cancer biology.

Autor: Donnem T; Department of Oncology, University Hospital of North Norway, Tromso, Norway.; Institute of Clinical Medicine, The Arctic University of Norway, Tromso, Norway., Reynolds AR; Tumour Biology Team, Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.; Oncology Translational Medicine Unit, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, UK., Kuczynski EA; Biological Sciences Platform, Sunnybrook Research Institute, Toronto, Canada.; Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, UK., Gatter K; Nuffield Department of Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, Oxford, UK., Vermeulen PB; Tumour Biology Team, Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.; Translational Cancer Research Unit, GZA, Hospitals St Augustinus, University of Antwerp, Wilrijk-Antwerp, Belgium.; HistoGeneX, Antwerp, Belgium., Kerbel RS; Biological Sciences Platform, Sunnybrook Research Institute, Toronto, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, Canada., Harris AL; Molecular Oncology Laboratories, Oxford University Department of Oncology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK., Pezzella F; Nuffield Department of Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, Oxford, UK.

Publikováno v: Nature reviews. Cancer [Nat Rev Cancer] 2018 May; Vol. 18 (5), pp. 323-336. Date of Electronic Publication: 2018 Mar 09.

Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.

Autor: Bridgeman VL; Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK., Vermeulen PB; Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.; Translational Cancer Research Unit (TCRU), GZA Hospitals St Augustinus, Antwerp, Belgium., Foo S; Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK., Bilecz A; 2nd Institute of Pathology, Semmelweis University, Budapest, Hungary., Daley F; Breast Cancer Now Histopathology Core Facility, The Royal Marsden, London, UK., Kostaras E; Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK., Nathan MR; Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK., Wan E; Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.; The Royal Marsden, London, UK., Frentzas S; Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.; The Royal Marsden, London, UK., Schweiger T; Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria., Hegedus B; Department of Thoracic Surgery, Ruhrlandklinik Essen, University Hospital of University Duisburg-Essen, Germany.; MTA-SE Molecular Oncology Research Group, Hungarian Academy of Sciences, Budapest, Hungary., Hoetzenecker K; Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria., Renyi-Vamos F; Department of Thoracic Surgery, Semmelweis University-National Institute of Oncology, Budapest, Hungary., Kuczynski EA; Department of Medical Biophysics, University of Toronto, Toronto, Canada., Vasudev NS; Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.; The Royal Marsden, London, UK.; Cancer Research UK Centre, Leeds Institute of Cancer and Pathology, St James's University Hospital, Leeds, UK., Larkin J; The Royal Marsden, London, UK., Gore M; The Royal Marsden, London, UK., Dvorak HF; Beth Israel Deaconess Medical Center, Boston, MA, USA., Paku S; 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.; Tumour Progression Research Group, Hungarian Academy of Sciences-Semmelweis University, Budapest, Hungary., Kerbel RS; Department of Medical Biophysics, University of Toronto, Toronto, Canada.; Biological Sciences Platform, Sunnybrook Research Institute, Toronto, Canada., Dome B; Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria.; Department of Thoracic Surgery, Semmelweis University-National Institute of Oncology, Budapest, Hungary.; National Koranyi Institute of Pulmonology, Budapest, Hungary.; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Austria., Reynolds AR; Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.

Publikováno v: The Journal of pathology [J Pathol] 2017 Feb; Vol. 241 (3), pp. 362-374. Date of Electronic Publication: 2016 Dec 29.